GlycoNex (4168) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlycoNex (4168) has a cash flow conversion efficiency ratio of -0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-17.29 Million ≈ $-544.86K USD) by net assets (NT$1.01 Billion ≈ $31.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GlycoNex defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
GlycoNex - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GlycoNex's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GlycoNex Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoNex ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lavras Gold Corp
V:LGC
|
-0.018x |
|
Fluent Inc
NASDAQ:FLNT
|
-0.350x |
|
CAB Cakaran Corporation Bhd
KLSE:7174
|
0.245x |
|
Delta Djakarta Tbk
JK:DLTA
|
0.097x |
|
OFX Group Ltd
AU:OFX
|
0.923x |
|
Aditya Birla Money Limited
NSE:BIRLAMONEY
|
0.060x |
|
Rama Steel Tubes Limited
NSE:RAMASTEEL
|
-0.060x |
|
Geopacific Resources Ltd
AU:GPR
|
-0.010x |
Annual Cash Flow Conversion Efficiency for GlycoNex (2017–2024)
The table below shows the annual cash flow conversion efficiency of GlycoNex from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see GlycoNex market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.05 Billion ≈ $32.97 Million |
NT$-221.97 Million ≈ $-6.99 Million |
-0.212x | -47.20% |
| 2023-12-31 | NT$1.28 Billion ≈ $40.21 Million |
NT$-183.92 Million ≈ $-5.79 Million |
-0.144x | -24.32% |
| 2022-12-31 | NT$1.45 Billion ≈ $45.54 Million |
NT$-167.55 Million ≈ $-5.28 Million |
-0.116x | -11.81% |
| 2021-12-31 | NT$1.36 Billion ≈ $42.81 Million |
NT$-140.86 Million ≈ $-4.44 Million |
-0.104x | -9.61% |
| 2020-12-31 | NT$1.54 Billion ≈ $48.51 Million |
NT$-145.59 Million ≈ $-4.59 Million |
-0.095x | +31.50% |
| 2019-12-31 | NT$1.30 Billion ≈ $40.98 Million |
NT$-179.58 Million ≈ $-5.66 Million |
-0.138x | -17.31% |
| 2018-12-31 | NT$1.53 Billion ≈ $48.28 Million |
NT$-180.34 Million ≈ $-5.68 Million |
-0.118x | -452.73% |
| 2017-12-31 | NT$1.84 Billion ≈ $58.01 Million |
NT$61.43 Million ≈ $1.94 Million |
0.033x | -- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more